Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 41063661.
- Also identified by DOI 10.1093/infdis/jiaf519 and PMC identifier 12875391.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Doxycycline treats and prevents several bacterial and parasitic infections and has been proposed as a possible treatment for Trichomonas vaginalis. Nested in a trial of doxycycline postexposure prophylaxis among cisgender women in Kenya, we conducted a secondary analysis of incident T. vaginalis infections. Among 224 cisgender women randomized to doxycycline postexposure prophylaxis and 225 to standard-of-care, there were 27 T. vaginalis diagnoses in the doxycycline postexposure prophylaxis group and 29 in the standard-of-care group (RR: 0.96, 95% CI: 0.54-1.73, P = .9). Understanding doxycycline postexposure prophylaxis's impact on T. vaginalis remains an important public health question that warrants further investigation.
Medical subject headings
- Doxycycline
- Trichomonas vaginalis
- Post-Exposure Prophylaxis
- Anti-Bacterial Agents
- Trichomonas Vaginitis
- Trichomonas Infections